Chemogenetic CRISPR screens to identify modulators of response to the CDK4/6 inhibitor abemaciclib in experimental glioma

We here used CRISPR screens, both in knockout as well as activation modality, to identify genetic hits that are capable of modifying the response of experimental glioma cell lines to CDK4/6 inhibition via abemaciclib. For knockout screens, the genome-wide Brunello sgRNA library was used. These screens were performed in LN229 and GS-9 cell lines. For activation screens, we used the Calabrese SetA sgRNA library. These screens were performed in LN229, LN18, LNZ308, T98G, and GS-9 cells. Raw sgRNA read counts provided here were quantified using PoolQ. For all screens, both DMSO and abemaciclib-treated drug arms are provided, both in duplicates. For reference, sgRNA read counts from the corresponding plasmid pool used to generate virus are given as well.